hVIVO plc (LSE:HVO) has issued its Annual Report and Accounts for the year ended 31 December 2025, alongside the formal Notice of Annual General Meeting. Shareholders can now access the full set of documents, including proxy voting materials, via the company’s website.
The AGM is scheduled for 13 May 2026 and will be held at the offices of DAC Beachcroft in the City of London. The meeting will provide shareholders with the opportunity to vote on key resolutions and engage with management on the company’s performance and strategy. The release of these materials represents a standard but important step in hVIVO’s corporate governance and investor engagement process.
The company’s broader outlook remains supported by strong financial performance, including solid revenue growth and a low-leverage balance sheet. While technical indicators suggest positive momentum, the share price continues to trade below key moving averages, indicating potential resistance. Its relatively low valuation multiple and modest dividend yield may appeal to both value and income-focused investors.
More about hVIVO plc
hVIVO plc is a UK-based full-service clinical development specialist and a global leader in human challenge trials, partnering with seven of the world’s ten largest biopharma companies. The group provides end-to-end services ranging from preclinical consulting through to early-stage clinical trials, supported by advanced virology and immunology laboratories.
Operating across four core divisions—Consulting, Clinical Trials, Human Challenge Trials, and Laboratories—hVIVO focuses on accelerating proof-of-concept studies for vaccines and therapeutics. Its dedicated quarantine facility in London enables controlled viral exposure trials, while its FluCamp platform supports volunteer recruitment and long-term biobanking for ongoing research initiatives.
Leave a Reply